Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175649-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $69.90 | |
Ab175649-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $339.90 | |
Ab175649-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $869.90 | |
Ab175649-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,379.90 |
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Rovelizumab (anti-CD11a&CD18) - Primary antibody, specific to ITGAL; ITGB2, Human IgG4 |
---|---|
Synonyms | Hu23F2G;LeukArrest |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Biochemical and Physiological Mechanisms | CD11a: Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granuloc |
Specificity | ITGAL; ITGB2 |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | ANTAGONIST |
Mechanism of action | Antibody of integrin; alpha L subunit (antigen CD11A (p180); lymphocyte function-associated antigen 1; alpha polypeptide);Antibody of integrin; beta 2 subunit (complement component 3 receptor 3 and 4 subunit) |
Product Description | Rovelizumab (anti-CD11a&CD18) is a humanized monoclonal leukointegrin antibody. Rovelizumab (anti-CD11a&CD18) is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab (anti-CD11a&CD18) can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke. |
Isotype | Human IgG4 |
---|---|
Light Chain Type | kappa |
SDS-PAGE | 145.98 kDa |
Purification Method | Protein A purified |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 339086-79-2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 304 |
---|
Enter Lot Number to search for COA:
1. Hu X, Wohler JE, Dugger KJ, Barnum SR. (2010) beta2-integrins in demyelinating disease: not adhering to the paradigm.. J Leukoc Biol, 87 (3): (397-403). [PMID:20007244] |
2. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. (2005) ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.. Blood, 106 (2): (584-92). [PMID:15811956] |
3. Mazzone A, Ricevuti G. (1995) Leukocyte CD11/CD18 integrins: biological and clinical relevance.. Haematologica, 80 (2): (161-75). [PMID:7628754] |
4. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S, Whitaker S, Steinberg GK. (1998) Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia.. Exp Neurol, 153 (2): (223-33). [PMID:9784282] |